trending Market Intelligence /marketintelligence/en/news-insights/trending/mQoI77q65pXW4FK3BPHvFQ2 content esgSubNav
In This List

US FDA approves Teva's drug for chorea linked to Huntington's disease

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA approves Teva's drug for chorea linked to Huntington's disease

The U.S. FDA approved Teva Pharmaceutical Industries Ltd.'s AUSTEDO tablets for the treatment of chorea associated with Huntington's disease.

The FDA approval was based on results from a phase 3 study to assess the safety and efficacy of the drug in reducing chorea in patients with the disease.

Previously, the agency granted the drug an orphan drug designation in 2014.